|
|
Post by akemp3000 on Jan 12, 2021 3:39:37 GMT -5
So now it's confirmed that Andrea Leone-Bay is moving forward with TS to treat both migraines and panic attacks with the latter being a first-in-class drug treatment. Al Mann must be smiling especially since his wife suffered from migraines. It's taking forever but he was right all along. IMO, MNKD will one day be one of the world's leading drug companies, if not absorbed, and the time frame just became a little bit shorter.
|
|
|
|
Post by stevil on Jan 12, 2021 8:38:31 GMT -5
I'm curious to see the trial results of the inhaled cannabinoid for panic attacks. There actually would be a huge market for that class. Right now there are only a few decent options- mostly Atarax and Buspar that are not benzodiazepines. Currently, SSRI's and psychotherapy are first line for panic attacks, but SSRIs are medications you need to take for weeks before their effect kicks in and good luck finding people who will do therapy when they can pop a pill instead, never mind the added time and expense that comes with it since insurance doesn't always cover those sessions. So I'm excited to see that one for sure- could be huge potential if it works well without side effects.
As far as migraine goes, I've been on here in the past to share my lack of excitement over an inhaled -triptan. Not that it wouldn't be a great idea to throw our hat in the ring and see what happens. It's just that there are already so many other options- oral, liquid, nasal spray, IM injection- that I really don't see much of a market for it, at least a market that will make MNKD a lot of money. Generics are cheap and it's highly unlikely insurance will pay a premium when there are already so many other options. I can see reimbursement being a huge issue. I've also stated that if they really want to get into the migraine space that they should get into the cGRP meds like Aimovig that are currently IM. I think there's an oral tablet coming in the future that could negate an inhaled option, but at least for now, this seems to be the future of migraine medicine. They're insanely expensive and they have no side effects and patients love them.
|
|
|
|
Post by Thundersnow on Jan 12, 2021 9:25:56 GMT -5
So now it's confirmed that Andrea Leone-Bay is moving forward with TS to treat both migraines and panic attacks with the latter being a first-in-class drug treatment. Al Mann must be smiling especially since his wife suffered from migraines. It's taking forever but he was right all along. IMO, MNKD will one day be one of the world's leading drug companies, if not absorbed, and the time frame just became a little bit shorter. Can you explain......>>IMO, MNKD will one day be one of the world's leading drug companies<< I doubt that. MNKD do not create/develop new Drugs. They reformulate drugs using their technology. MNKD gets Royalties (10-13%). That's a far cry from 100%......MNKD needs to be smart (which they are) to partner with the owners or market leaders as opposed to going alone. They could end up like LQDA and be in COURT HELL.... |
|
|
|
Post by akemp3000 on Jan 12, 2021 10:21:29 GMT -5
I'm curious to see the trial results of the inhaled cannabinoid for panic attacks. There actually would be a huge market for that class. Right now there are only a few decent options- mostly Atarax and Buspar that are not benzodiazepines. Currently, SSRI's and psychotherapy are first line for panic attacks, but SSRIs are medications you need to take for weeks before their effect kicks in and good luck finding people who will do therapy when they can pop a pill instead, never mind the added time and expense that comes with it since insurance doesn't always cover those sessions. So I'm excited to see that one for sure- could be huge potential if it works well without side effects. As far as migraine goes, I've been on here in the past to share my lack of excitement over an inhaled -triptan. Not that it wouldn't be a great idea to throw our hat in the ring and see what happens. It's just that there are already so many other options- oral, liquid, nasal spray, IM injection- that I really don't see much of a market for it, at least a market that will make MNKD a lot of money. Generics are cheap and it's highly unlikely insurance will pay a premium when there are already so many other options. I can see reimbursement being a huge issue. I've also stated that if they really want to get into the migraine space that they should get into the cGRP meds like Aimovig that are currently IM. I think there's an oral tablet coming in the future that could negate an inhaled option, but at least for now, this seems to be the future of migraine medicine. They're insanely expensive and they have no side effects and patients love them. "About 20 to 25 percent of people have had a panic attack, Hajcak says, though only 2 to 3 percent go on to develop panic disorder, which is a vicious cycle that leads to anxiety about the prospect of having more panic attacks in the future. Anyone who has had a single panic attack would be willing to pay a lot for rapid relief. I know little about migraines but there are wise people here who can share their knowledge. It's my understanding that all of the currently available options take excessively long to be effective and this is why the RLS deep lung inhalation is being designated first-in-class. If this also offers speed of relief comparable to the panic attacks, I can see why Andrea Leone-Bay left Mannkind to join RLS but has stayed deeply connected to TS. |
|
|
|
Post by boca1girl on Jan 12, 2021 21:56:35 GMT -5
I'm curious to see the trial results of the inhaled cannabinoid for panic attacks. There actually would be a huge market for that class. Right now there are only a few decent options- mostly Atarax and Buspar that are not benzodiazepines. Currently, SSRI's and psychotherapy are first line for panic attacks, but SSRIs are medications you need to take for weeks before their effect kicks in and good luck finding people who will do therapy when they can pop a pill instead, never mind the added time and expense that comes with it since insurance doesn't always cover those sessions. So I'm excited to see that one for sure- could be huge potential if it works well without side effects. As far as migraine goes, I've been on here in the past to share my lack of excitement over an inhaled -triptan. Not that it wouldn't be a great idea to throw our hat in the ring and see what happens. It's just that there are already so many other options- oral, liquid, nasal spray, IM injection- that I really don't see much of a market for it, at least a market that will make MNKD a lot of money. Generics are cheap and it's highly unlikely insurance will pay a premium when there are already so many other options. I can see reimbursement being a huge issue. I've also stated that if they really want to get into the migraine space that they should get into the cGRP meds like Aimovig that are currently IM. I think there's an oral tablet coming in the future that could negate an inhaled option, but at least for now, this seems to be the future of migraine medicine. They're insanely expensive and they have no side effects and patients love them. "About 20 to 25 percent of people have had a panic attack, Hajcak says, though only 2 to 3 percent go on to develop panic disorder, which is a vicious cycle that leads to anxiety about the prospect of having more panic attacks in the future. Anyone who has had a single panic attack would be willing to pay a lot for rapid relief. I know little about migraines but there are wise people here who can share their knowledge. It's my understanding that all of the currently available options take excessively long to be effective and this is why the RLS deep lung inhalation is being designated first-in-class. If this also offers speed of relief comparable to the panic attacks, I can see why Andrea Leone-Bay left Mannkind to join RLS but has stayed deeply connected to TS. My comments on migraines: I’ve only had a few in my lifetime but my niece has suffered with them from about age 5. Your head feels like it could explode and are debilitating. The current self administered treatments take an hour or more to start working. Serena Williams (tennis star) is now advertising for Ubrelvy. From their website, “People took UBRELVY within 4 hours of a migraine attack. In clinical studies, many people had pain relief and some even had pain freedom within two hours.” I’m assuming that a product using Technosphere would be much faster acting. I think the market would be pretty attractive for fast acting relief and similar to Afrezza and it’s competitors. |
|
|
|
Post by sportsrancho on Jan 12, 2021 22:33:52 GMT -5
My girlfriend used to have to lay on the floor in the dark with ice on her head while she waited 45-minutes to an hour for her migraine pain medication to work. The pain was so bad she couldn’t open her eyes.
Also I had another girlfriend who used to have panic attacks daily she got to the point where she did not want to leave her house, she was afraid if she did she would either have a heart attack or pass out. She was in therapy and the times when she finally made it to the therapist she was dripping sweat.
|
|
|
|
Post by u1682002 on Jan 12, 2021 23:09:51 GMT -5
Does anyone have idea how much stake that MNKD has in RLS? In another word, how much can MNKD stock holder can benefit from RLS’ s future success?
|
|
|
|
Post by boca1girl on Jan 12, 2021 23:24:16 GMT -5
Does anyone have idea how much stake that MNKD has in RLS? In another word, how much can MNKD stock holder can benefit from RLS’ s future success? Matt P. claimed from the start that MNKD had no financial stake in RLS. Many here question that. Publicly we know that there is up to $101m in milestone payments of which we collected $1m so far and royalties for their products using Technosphere. |
|
|
|
Post by mango on Jan 12, 2021 23:40:09 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 13, 2021 10:37:11 GMT -5
Does anyone have idea how much stake that MNKD has in RLS? In another word, how much can MNKD stock holder can benefit from RLS’ s future success? Matt P. claimed from the start that MNKD had no financial stake in RLS. Many here question that. Publicly we know that there is up to $101m in milestone payments of which we collected $1m so far and royalties for their products using Technosphere. Milestone payments are not EQUITY. MNKD does not own EQUITY in RLS if they did it would have to be disclosed in the 10-K. |
|
|
|
Post by akemp3000 on Jan 13, 2021 11:19:22 GMT -5
Does anyone know if Andrea Leone-Bay, who left Al and Mannkind a couple of years ago to help start RLS, still works out of the Mannkind facility?
|
|
|
|
Post by jay1ajay1a on Jan 13, 2021 12:03:45 GMT -5
From LinkedIn
Andrea Leone-Bay
3rd degree connection3rd
Andrea has a account
Chief Scientific Officer at Receptor Life Sciences
Danbury, Connecticut, United States 280 connections Contact info
|
|
|
|
Post by mango on Jan 13, 2021 12:11:01 GMT -5
Does anyone know if Andrea Leone-Bay, who left Al and Mannkind a couple of years ago to help start RLS, still works out of the Mannkind facility? You mean here?  |
|
|
|
Post by letitride on Jan 13, 2021 21:20:51 GMT -5
This is going to be good. LMAO
Lets Go!
|
|
|
|
Post by sportsrancho on Jan 14, 2021 10:46:19 GMT -5
Does anyone know if Andrea Leone-Bay, who left Al and Mannkind a couple of years ago to help start RLS, still works out of the Mannkind facility? :-) |
|
